References of "vermeire, S"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailProfile of pediatric Crohn's disease in Belgium.
De Greef, E.; Mahachie John, Jestinah ULg; Hoffman, I. et al

in Journal of Crohn's & colitis (2013), 7(11), 588-98

AIM: A Belgian registry for pediatric Crohn's disease, BELCRO, was created. This first report aims at describing disease presentation and phenotype and determining associations between variables at ... [more ▼]

AIM: A Belgian registry for pediatric Crohn's disease, BELCRO, was created. This first report aims at describing disease presentation and phenotype and determining associations between variables at diagnosis and registration in the database. METHODS: Through a collaborative network, children with previously established Crohn's disease and newly diagnosed children and adolescents (under 18 y of age) were recruited over a 2 year period. Data were collected by 23 centers and entered in a database. Statistical association tests analyzed relationships between variables of interest at diagnosis. RESULTS: Two hundred fifty-five patients were included. Median age at diagnosis was 12.5 y (range: 1.6-18 y); median duration of symptoms prior to diagnosis was 3 m (range: 1-12 m). Neonatal history and previous medical history did not influence disease onset nor disease behavior. Fifty three % of these patients presented with a BMI z-score < -1. CRP was an independent predictor of disease severity. Steroids were widely used as initial treatment in moderate to severe and extensive disease. Over time, immunomodulators and biological were prescribed more frequently, reflecting a lower prescription rate for steroids and 5-ASA. A positive family history was the sole significant determinant for earlier use of immunosuppression. CONCLUSION: In Belgium, the median age of children presenting with Crohn's disease is 12.5 y. Faltering growth, extensive disease and upper GI involvement are frequent. CRP is an independent predictive factor of disease activity. A positive family history appears to be the main determinant for initial treatment choice. [less ▲]

Detailed reference viewed: 55 (24 ULg)
Full Text
Peer Reviewed
See detailActive Foxp3 (+) Regulatory T Cells Rather Than Other Foxp3 (+) T Cells Subsets CorrelateWith Clinical Response To Infliximab Therapy For IBD
Li, Z; Vermeire, S; Bullens, D et al

Poster (2012, October)

Detailed reference viewed: 2 (1 ULg)
Full Text
Peer Reviewed
See detailRestoration Of B Cells Correlates With Clinical Response To Anti-Tnf Therapy
Li, Z; Vermeire, S; Bullens, D et al

Poster (2012, October)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailFactors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn's disease patients (BELCRO)
De Greef, E; Mahachie John, Jestinah; Hoffman, I et al

in Gastroenterology (2012)

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailSequential T2 Relaxometry as a Non-Invasive Assessment of Transmural Inflammation in a Murine Model of Chronically Relapsing Colitis
Breynaert, C; Dresselaers, T; Cremer, J et al

Poster (2012, May)

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailRepeated cycles of DSS inducing a chronically relapsing inflammation: a novel model to study fibrosis using in vivo MRI T2 relaxometry
Breynaert, C; Dresselaers, T; Cremer, J et al

Poster (2012, May)

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailGenetic and functional evidence for a role of CYLD in Crohn’s Disease: results from a European consortium
Cleynen, I; Vazeille, E; Artieda, M et al

in Journal of Crohn’s and Colitis [=JCC] (2012)

Detailed reference viewed: 19 (5 ULg)
Full Text
Peer Reviewed
See detailMultiple functional variants at the 3p21 locus contribute to ulcerative colitis: Results from a European consortium
Cleynen, I; Artieda, M; Verspaget, H et al

in Journal of Crohn’s and Colitis [=JCC] (2012)

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailRepeated cycles of DSS inducing a chronically relapsing inflammation: A novel model to study fibrosis using in vivo MRI T2 relaxometry
Breynaert, C; Dresselaers, T; Cremer, J et al

Poster (2012, February)

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailFactors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn’s disease patients (BELCRO)
De Greef, E; Mahachie John, Jestinah; Hoffman, I et al

in Acta Gastro-Enterologica Belgica (2012)

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailSafety And Cost Of Infliximab For The Treatment Of Belgian Pediatric Patients With Crohn’s Disease
De Greef, E; Hoffman, I; D'haens, G et al

in Journal of Crohn’s and Colitis (2012)

Detailed reference viewed: 36 (2 ULg)
Full Text
Peer Reviewed
See detailSafety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
De Greef, E.; Hoffman, I.; D'Haens, G. et al

in Acta Gastro-Enterologica Belgica (2012), 75(4), 425-31

Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in ... [more ▼]

Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD. [less ▲]

Detailed reference viewed: 27 (8 ULg)
Full Text
Peer Reviewed
See detailFast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis.
De Vos, M.; Dewit, Olivier; D'Haens, G. et al

in Journal of Crohn’s and Colitis [=JCC] (2012), 6(5), 557-62

AIM: To evaluate the effect of infliximab induction therapy on calprotectin levels in patients with ulcerative colitis (UC). PATIENTS AND METHODS: In this prospective study 53 patients with active UC from ... [more ▼]

AIM: To evaluate the effect of infliximab induction therapy on calprotectin levels in patients with ulcerative colitis (UC). PATIENTS AND METHODS: In this prospective study 53 patients with active UC from 17 centers were treated with infliximab therapy (5 mg/kg) at baseline, week 2, and week 6. Faecal calprotectin was measured every week. Sigmoidoscopies were performed at baseline, week 6 and week 10. RESULTS: Median calprotectin levels decreased from 1260 (IQR 278.5- 3418) at baseline to 72.5 (IQR 18.5 - 463) at week 10 (p<0.001). After 10 weeks, infliximab therapy induced endoscopic remission and a decrease in calprotectin to<50 mg/kg or at least a 80% decrease from baseline level in 58% of patients. A significant and steep decrease of calprotectin levels was seen at week 2 for patients with an endoscopic remission at week 10 as compared to patients who did not show a remission. (p<0.001). At week 10 an excellent correlation was found between endoscopic remission and clinical Mayo score reflected by an AUC of ROC analyses of 0.94 (0.87-1) and with calprotectin measurements (AUC 0.91 (0.81-1)) : all patients with calprotectin levels <50 mg/kg, and a normal clinical Mayo score (=0) were in endoscopic remission. CONCLUSIONS: Infliximab induces a fast and significant decrease of faecal calprotectin levels in anti-TNF naive patients with ulcerative colitis predictive for remission of disease. [less ▲]

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailTolerability of shortened infliximab infusion times in patients with inflammatory bowel disease: a single center cohort study
Breynaert, C; Ferrante, F; Fidder, H et al

in Acta Gastro-Enterologica Belgica (2011)

Detailed reference viewed: 28 (3 ULg)
Full Text
Peer Reviewed
See detailLong term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease
Drobne, D; Bossuyt, P; Breynaert, C et al

in Journal of Crohn’s and Colitis [=JCC] (2011)

Detailed reference viewed: 36 (1 ULg)
Full Text
Peer Reviewed
See detailThe protease genes CYLD and USP40 are associated with Crohn's disease: results from a European Consortium
Cleynen, I; Artieda, M; Szczyoiorska, M et al

in Gastroenterology (2011), 140(5), 269

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailAnti-TNF induced skin manifestations in IBD patients: characterization and search for predisposing factors
Cleynen, I; Van Moerkercke, W; Vande Casteele, N et al

in Acta Gastro-Enterologica Belgica (2011), 74

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis
De Greef, E; Hoffman, I; Smets, F et al

in Gastroenterology (2011), 140(5), 787

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis
De Greef, E; Hoffman, I; Smets, F et al

in Acta Gastro-Enterologica Belgica (2011), 74

Detailed reference viewed: 7 (1 ULg)